ClinicalTrials.Veeva

Menu
A

Amicis Research Center | Northridge, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BI 690517
Empagliflozin
Lorundrostat
GFB-887
Dapagliflozin
IMG-007
Camoteskimab
SAR441566
AND017
Tildrakizumab

Parent organization

This site is a part of Amicis Research Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 27 total trials

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling
Lupus Erythematosus, Systemic
Drug: Cenerimod
Drug: Placebo
Recently updated

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388...

Active, not recruiting
Overweight
Obesity
Drug: CT-388
Drug: Placebo

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Active, not recruiting
Atopic Dermatitis
Eczema Atopic Dermatitis
Drug: Placebo
Drug: Camoteskimab

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Active, not recruiting
Rheumatoid Arthritis
Drug: SAR441566
Drug: Placebo

Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Enrolling
Moderate to Severe Genital Psoriasis
Drug: Tildrakizumab 100 mg
Drug: Placebo

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to e...

Enrolling
Primary Membranous Nephropathy
Drug: Tacrolimus
Drug: Zanubrutinib
Locations recently updated

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Enrolling
Heart Failure
Drug: Placebo matching vicadrostat
Drug: Empagliflozin

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Active, not recruiting
Asthma
Drug: Placebo
Drug: Lunsekimig

This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and...

Active, not recruiting
Chronic Kidney Disease
Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
Drug: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting
IgA Nephropathy
Drug: BION-1301 Multiple Doses
Drug: Placebo Multiple Doses

Trial sponsors

Amgen logo
Boehringer Ingelheim logo
G
Idorsia Pharmaceuticals logo
M
Sanofi logo
A
BeiGene logo
B
Biogen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems